Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutica...( CHAPEL HILL N.C. May 22 /- Pharma...)

CHAPEL HILL, N.C., May 22 /PRNewswire/ -- Pharmaceutical and biotech companies increasingly are adopting a Risk-Based Approach (RBA) in their Quality Assurance (QA) functions. This benchmarking study will help R&D Quality Assurance executives tackle two current challenges:

-- Optimizing limited QA staff resources so that they have the most

effect

-- Optimizing services in regards to the FDA's Risk-Bases method for

selecting inspection sites

The study assesses the size of QA organizations relative to the size of the R&D functional areas they serve. Organizations are also evaluated on their implementation of Risk-Based Approach and its impact on QA workload and management.

For specific research topic included in the study download a complimentary sample of this research, "Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutical Industry," at http://www3.best-in-class.com/br128.htm .

"Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutical Industry" reflects the type of research Best Practices, LLC conducts for members of its Business Excellence Board ( http://www3.best-in-class.com/beb ), a research and advisory service for health care and pharmaceutical executives.

For information on other services by Best Practices, LLC and its Business Excellence Board, contact Cameron Tew at ctew@best-in-class.com or 919-403-0251, ext. 246.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. For more than 15 years, our highly credentialed research staff has conducted primary research
'/>"/>